Initial exploration of the feasibility of dual checkpoint blockade in preclinical mouse models demonstrated that the combination of anti-CTLA-4 and anti-PD-1 enhanced anti-tumor activity compared to either regimen alone [37]. This evidence concerns the gene CTLA4 and neoplasm.